Press-release for stocks in the commercial services sector related to fda

Prices are updated after-hours

sector : Commercial services tags : Fda

save search

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
Published: 2023-11-07 (Crawled : 14:00) - globenewswire.com
SLRX A | $0.486 -2.8% -2.88% 110K

Commercial Services

| -37.5% | O: 11.25% H: 4.49% C: -6.85%
fda seclidemstat meeting program

Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Published: 2023-10-26 (Crawled : 12:00) - globenewswire.com
ALT | $7.05 -6.25% -6.67% 3.6M

Commercial Services

| 217.3% | O: 11.81% H: 3.02% C: -12.45%
fda granted treatment designation

Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients
Published: 2023-07-11 (Crawled : 12:20) - globenewswire.com
SLRX A | $0.486 -2.8% -2.88% 110K

Commercial Services

| -65.52% | O: 3.45% H: 0.01% C: -15.33%
sp-3164 fda drug clearance pharmaceuticals application trial

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma
Published: 2023-05-09 (Crawled : 12:00) - globenewswire.com
SLRX A | $0.486 -2.8% -2.88% 110K

Commercial Services

| -76.85% | O: 6.48% H: 0.43% C: -21.3%
fda seclidemstat trial

Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology
Published: 2023-05-09 (Crawled : 11:00) - globenewswire.com
ADPT | News | $2.435 -11.46% -12.94% 3.3M

Commercial Services

| -58.33% | O: 0.76% H: 9.17% C: 5.41%
fda drug t-cell application therapy

OpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary Tract Infection Panel
Published: 2023-04-18 (Crawled : 12:00) - globenewswire.com
OPGN A | $0.621 -3.62% -3.75% 130K

Commercial Services

| -46.63% | O: 3.55% H: 1.6% C: -16.0%
fda infection

ALX Oncology’s Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma
Published: 2022-08-01 (Crawled : 23:00) - biospace.com/
ALXO | $16.08 10.97% 9.89% 2M

Commercial Services

| 49.69% | O: 2.07% H: 1.42% C: -4.66%
treatment fda designation cell carcinoma fast track designation

Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for ObesityEnrollment in 48-week Phase 2 clinical trial expected to begin in Q1 2022
Published: 2022-01-31 (Crawled : 15:00) - biospace.com/
ALT | $7.05 -6.25% -6.67% 3.6M

Commercial Services

| 4.44% | O: 2.92% H: 9.31% C: 8.91%
alt-801 fda obesity phase 2 clearance trial fda clearance

ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction Cancer
Published: 2022-01-27 (Crawled : 23:00) - globenewswire.com
ALXO | $16.08 10.97% 9.89% 2M

Commercial Services

| 0.91% | O: -1.81% H: 8.01% C: 7.8%
treatment fda drug orphan drug cancer designation

Applied DNA Submits Request for Emergency Use Authorization to FDA for Linea™ 2.0 COVID-19 Assay and Linea™ Unsupervised At-Home Sample Collection Kit
Published: 2022-01-21 (Crawled : 17:00) - biospace.com/
ARVL | News | $0.49 0.37% 2.5M

Manufacturing

| -90.75% | O: -15.97% H: 0.0% C: 0.0%
APDN | $0.3295 -4.3% -4.49% 84K

Commercial Services

| -91.19% | O: -0.77% H: 0.0% C: 0.0%
covid-19 fda covid authorization merge emergency use authorization

Request for FDA EUA for Linea™ 2.0 COVID-19 Assay, Linea™ Unsupervised At-Home Sample Collection Kit
Published: 2022-01-21 (Crawled : 16:00) - adnas.com
ARVL | News | $0.49 0.37% 2.5M

Manufacturing

| -90.75% | O: -15.97% H: 0.0% C: 0.0%
APDN | $0.3295 -4.3% -4.49% 84K

Commercial Services

| -91.19% | O: -0.77% H: 0.0% C: 0.0%
covid-19 fda covid

Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate Update
Published: 2022-01-18 (Crawled : 13:00) - biospace.com/
CELC | $16.96 -1.57% -1.59% 120K

Commercial Services

| 49.18% | O: -2.16% H: 7.88% C: 2.12%
fast track designation fda fast track cel fda fast track cancer breast cancer designation her2- her2 metastatic breast cancer

Pharmaceutical Analytical Testing Outsourcing Market to grow by USD 3.21 bn| Increased Number of FDA-approved Manufacturing Facilities in Developing Nations to Boost Market Growth | 17000+ Technavio Reports
Published: 2021-12-16 (Crawled : 11:00) - prnewswire.com
IKTSY | $59.99 -12.21% 1.9K

Professional, Scientific, and T...

| -17.83% | O: -0.1% H: 0.0% C: -0.14%
fda test growth

COVID-19 Update: FDA Vaccine Approval, Booster Shots, and Trying to Conceive
Published: 2021-11-01 (Crawled : 18:00) - progyny.com
PGNY | News | $32.71 -2.04% -2.08% 640K

Commercial Services

| -45.65% | O: 0.28% H: 2.64% C: 0.65%
covid fda vaccine approval covid-19

COVID-19 Update Webinar: FDA Vaccine Approval, Booster Shots, and Trying to Conceive
Published: 2021-11-01 (Crawled : 13:00) - progyny.com
PGNY | News | $32.71 -2.04% -2.08% 640K

Commercial Services

| -45.65% | O: 0.28% H: 2.64% C: 0.65%
covid fda vaccine approval covid-19

APDN Submits FDA EUA Request for Linea™ SARS-CoV-2 Mutation Panel
Published: 2021-10-25 (Crawled : 14:00) - adnas.com
APDN | $0.3295 -4.3% -4.49% 84K

Commercial Services

| -93.91% | O: -1.77% H: 4.32% C: 2.88%
fda sars-cov-2

Applied DNA Submits Request for Emergency Use Authorization to FDA for Linea™ SARS-CoV-2 Mutation Panel
Published: 2021-10-25 (Crawled : 12:00) - biospace.com/
APDN | $0.3295 -4.3% -4.49% 84K

Commercial Services

| -93.91% | O: -1.77% H: 4.32% C: 2.88%
fda merge sars-cov-2 emergency use authorization

OpGen Receives FDA Clearance for Acuitas® AMR Gene Panel
Published: 2021-10-04 (Crawled : 12:00) - globenewswire.com
OPGN A | $0.621 -3.62% -3.75% 130K

Commercial Services